# Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer

> **NCT02626130** · EARLY_PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Cancer
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **PROCEDURE:** Cryosurgery
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Therapeutic Conventional Surgery
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT02626130
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-30
- **Primary completion:** 2022-06-20
- **Final completion:** 2022-06-20
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02626130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02626130, "Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02626130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*